Bioceltix (BCX) Q1 2025 earnings summary

Executive summary

• Achieved positive primary endpoint results in clinical trial for BCX-CM-AD for canine atopic dermatitis; registration as a new indication for BCX-CM-J planned.

• Registration process for BCX-CM-J (osteoarthritis in dogs) with EMA progressing, with most regulatory tasks completed and revalidation underway.

• Dossier for BCX-EM (equine osteoarthritis) submitted to EMA; formal review completed, substantive review started.

• Significant engagement with veterinary and capital markets, including presentations at major industry and investor conferences.

Financial highlights

• No revenue from product sales; company remains pre-commercial.

• Net loss for Q1 2025: PLN -3.79 million, compared to PLN -4.20 million in Q1 2024.

• Operating loss for Q1 2025: PLN -3.82 million.

• Cash and cash equivalents at March 31, 2025: PLN 32.57 million.

• Equity at March 31, 2025: PLN 34.62 million; total assets: PLN 39.31 million.

Outlook and guidance

• Focus remains on advancing clinical programs and regulatory submissions for BCX-CM-J, BCX-CM-AD, and BCX-EM.

• No financial forecasts published; continued investment in R&D and manufacturing scale-up expected.

• Anticipates continued losses until product commercialization.